Mpox (monkeypox) pathfinder

Contents: Guidance and procedures; Posters and fact sheets.

ASHM (Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine) mpox guidance, policy and position statements.

This is the landing page for access to all of WHO's mpox clinical management guidance.

Technical documents on mpox (monkeypox) for: Health professionals; Health sector preparation; Industry; and Laboratory personnel. | PHAC (Public Health Agency of Canada.

Contents: Guidance for health professionals and service providers; Vaccination guidance; Guidance for the general public, and Technical, epidemiological overview, monitoring and surveillance.

Guidelines for health professionals that outline the therapeutic options for the management of human Monkeypox virus infection and vaccine related complications.

ASHM (Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine) guidelines provide concise evidence-based information to support the prevention, testing, diagnosis, management and treatment of sexually transmissible infections (STIs) for adults and adolescents.

ASHM's (Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine) toolkit provides a range of resources as guidance for clinicians around monkeypox (mpox) case definitions, testing, treatment, contract tracing and vaccination. Some of the resources in this toolkit have been sourced from external organisations and government departments.

This is the landing page for access to all of WHO's mpox clinical management guidance.

Clinical management algorithm for suspected monkeypox virus exposure during pregnancy. These recommendations should be adapted to local guidelines and updated as more information arises. | Dashraath P, Nielsen-Saines K, Mattar C, et al. Guidelines for pregnant individuals with monkeypox virus exposure. Lancet. 2022 Jul 2;400(10345):21-22. doi:10.1016/S0140-6736(22)01063-7

Guidance for dermatologists on recognizing the signs of mpox infection. | Developed by the AAD's (American Academy of Dermatology Association) Ad Hoc Task Force to Develop Mpox Content.

AAD's (American Academy of Dermatology Association) clinical guidance on treating severe lesions associated with mpox. Includes resources for mpox coinfection.

This guidance has been designed for use among dermatologists and front-line clinicians in primary care, emergency medicine, and infectious diseases. It covers the mucocutaneous manifestations of monkeypox infection during the current outbreak, draw upon management of similar mucocutaneous conditions, and propose strategies for supportive care for patients with monkeypox infection. | Maredia H, Sartori-Valinotti JC, Ranganath N, et al. Supportive care management recommendations for mucocutaneous manifestations of monkeypox infection. Mayo Clinic Proceedings. 2023;98(6):828-832. doi: 10.1016/j.mayocp.2023.01.019

This collection provides information on testing and referring patients with suspected mpox, including how to safely and correctly collect and transport specimens. It is for general practitioners and sexual health physicians.

PHLN (Public Health Laboratory Network) information for general practitioners and sexual health physicians on referring patients with suspected Monkeypox. It also includes how to safely and correctly collect and transport specimens.

WHO's guidance on laboratory confirmation of mpox.

CDNA's (Communicable Diseases Network) interim guidelines describe recommended public health responses to cases and contacts of monkeypox virus infection. CDNA will continue to review these guidelines as more information becomes available.

This paper outlines AFAO and ASHM’s policy position on the collection and dissemination of mpox surveillance data. This paper notes that states and territories should issue mpox surveillance data relating to locally acquired cases as soon as possible as well as data relating to cases among returned travellers. | | AFAO (Australian Federation of AIDS Organisations) [AFAO has rebranded as Health Equity Matters] + ASHM (Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine).

This interim guidance applies to all countries and covers surveillance, case investigation and contact-tracing for mpox.

The aim of this document is to provide advice and considerations, based on currently available evidence, to EU/EEA public health authorities at national, regional or local levels, conducting contact tracing in the context of the ongoing monkeypox outbreak. This advice and considerations encompass the prioritisation of efforts to identify and manage close contacts, as well as provide indicators that can be used for monitoring the efficacy of contact tracing activities. | ECDC's (European Centre for Disease Prevention and Control) for the EU/EEA (European Economic Area).

Covers: Public health management of cases; and Public health management of contacts. PHAC (Public Health Agency Canada).

Classification of contacts and follow-up advice for non-high consequence infectious disease (HCID) mpox. This guidance provides principles for risk assessment and follow-up of contacts of confirmed mpox cases. It is intended to support risk assessment and categorisation of contacts to ensure they are offered appropriate public health and isolation advice.

Information sheets for category 2 and category 3 contacts.

CDNA's (Communicable Diseases Network) surveillance case definition for monkeypox virus infection, which is nationally notifiable within Australia.

Public Health Laboratory Network's (PHLN) standard laboratory case definition for the diagnosis of monkeypox in Australia.

The Toolbox includes the WHO mpox case definitions; data collection tools and laboratory confirmation guidance. | WHO (World Health Organization).

This Infection Prevention and Control Expert Group (ICEG) interim mpox guidance is intended for healthcare workers.

This Infection Prevention and Control Expert Group (ICEG) interim guidance is intended for people with monkeypox virus who are at home or in a non-healthcare setting.

This paper outlines considerations that health authorities can use to determine the appropriate level of isolation required to reduce mpox. The paper illustrates how jurisdictions can work with AIDS Councils in each state and territory to communicate with people who have mpox about how to prevent sexual and other skin to skin contact with others during isolation. | AFAO (Australian Federation of AIDS Organisations) [AFAO has rebranded as Health Equity Matters] + ASHM (Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine).

This paper outlines how sex-on-premises venues (SOPVs) may be the site of transmission for the mpox virus between gay, bisexual and other men who have sex with men (GBMSM). The paper describes strategies to mitigate the risk of transmission including cleaning the facility and supporting contact tracing. The paper also notes other ways SOPVs can engage more broadly with the public health response to mpox. | AFAO (Australian Federation of AIDS Organisations) [AFAO has rebranded as Health Equity Matters] + ASHM (Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine).

This interim guidance covers the clinical management and infection prevention and control of monkeypox for health care and community settings. Coverage includes clinical management considerations for specific population groups, the use of therapeutics, nutritional support, mental health services, and post-infection follow-up.

This document provides guidance on infection prevention and control (IPC) measures for primary and acute healthcare settings in the European Union/European Economic Area (EU/EEA) to prevent healthcare-associated transmission of monkeypox (MPX). | ECDC (European Centre for Disease Prevention and Control).

Covers: Transmission; Clinical progression and incubation period; Infection prevention and control; Additional precautions; Cleaning and disinfection; Containment and disposal of contaminated waster; Discharge environmental cleaning and disinfection; Transportation of suspected Monkeypox patients; and Occupational monkeypox exposures in healthcare settings. | PHAC (Public Health Agency Canada).

This resource is for people who operate non-health care community settings, particularly where activities that may increase the risk of mpox (monkeypox) transmission occur, such as: sex-on-premises venues and other gathering spaces; bars and nightclubs; congregate living settings like a shelter, residence or correctional facility; and recreational facilities. The purpose of the resource is to assist with identifying risk factors associated with mpox transmission, and to determine which public health measures could help reduce the risk of mpox spreading in your setting. | PHAC (Public Health Agency Canada).

A consensus statement outlining principles for the control of non-high-consequence infectious disease (HCID) mpox (monkeypox) in healthcare and other settings in the UK. | UK Health Security Agency, Public Health Wales and Public Health Agency (Northern Ireland).

Guidance on mpox classification, transportation of samples and cultures, appropriate handling of waste and IPC measures.

Guidance for people who have been diagnosed with a mpox infection and who have been advised to self-isolate at home.

Applies to England | Interim guidance to support NHS Trusts in managing the de-isolation and discharge of mpox-infected patients.

Advice to help lower the chance of passing mpox infection to others during post-exposure vaccination clinics.

This guidance is for owners, managers and staff of sex-on-premises venues, and gives advice on cleaning their venues in light of the recent increase in mpox infections in the UK.

This paper outlines AFAO and ASHM’s position that messages to gay, bisexual and other men who have sex with men (GBMSM) about mpox should be provided by GBMSM and other members of the LGBTQI+ community. The paper suggests that government and healthcare stakeholders partner with LGBTIA+ health and HIV organisations to provide messages on risk reduction and to avoid stigmatising sexual behaviour. | AFAO (Australian Federation of AIDS Organisations) [AFAO has rebranded as Health Equity Matters] + ASHM (Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine).

This paper outlines the minimum services that governments should fund to enable AIDS Councils in each state and territory to be effective in the response to mpox. The paper describes the core services that AIDS Councils in each state and territory should be able to provide, which include running independent digital campaigns, community forums, sector forums, peer support and monitoring the media. | | AFAO (Australian Federation of AIDS Organisations) [AFAO has rebranded as Health Equity Matters] + ASHM (Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine).

The guidance includes: Recommendations on identifying and communicating with affected populations and key audiences and avoiding stigma in communications outreach; Key messages about symptoms of monkeypox, transmission, prevention measures, and communicating about uncertainty; and Guidance for managers and planners of gatherings and events, where close physical contact may create an environment conducive for the transmission of monkeypox.

This resource is for people who operate non-health care community settings, particularly where activities that may increase the risk of mpox (monkeypox) transmission occur, such as: sex-on-premises venues and other gathering spaces; bars and nightclubs; congregate living settings like a shelter, residence or correctional facility; and recreational facilities. The purpose of the resource is to assist with identifying risk factors associated with mpox transmission, and to determine which public health measures could help reduce the risk of mpox spreading in your setting. | PHAC (Public Health Agency Canada).

Public health principles to support planning for events and mass gatherings during the current mpox outbreak.

SEE: 6. Antivirals and other therapies (1 recommendation)

While there is not yet sufficient evidence to inform clinical management guidelines, WHO has developed the emergency use protocol for tecovirimat for mpox under the MEURI (Monitored Emergency Use of Unregistered and Experimental Interventions) framework.
NB: Please scroll down the screen to view the protocol.

BHIVA's (British HIV Association) rapid guidance on the safety and efficacy of mpox vaccines and therapeutics for people with HIV who have contracted mpox.

ATAGI (Australian Technical Advisory Group on Immunisation)

Information about mpox (previously known as monkeypox) disease, vaccines and recommendations for vaccination.

Guidelines for health professionals that outline the therapeutic options for the management of human Monkeypox virus infection and vaccine related complications.

SAGE's (Strategic Advisory Group of Experts on Immunization) current position paper is concerned with vaccines and vaccination against mpox and smallpox and includes off-label recommendations. For the latest SAGE updates/alerts go to: https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization. PLEASE NOTE: This document replaces the 2022 interim guidance on mpox vaccination and the 2014 meeting report on smallpox vaccines and smallpox vaccination.

World Health Organization (WHO) has announced the MVA-BN (Modified vaccinia Ankara-Bavarian Nordic) vaccine as the first vaccine against mpox to be added to its prequalification list 13/9/2024.

Information in this document provides additional details on shipment, storage temperatures, shelf-life, and supportive temperature excursion information to support distributors and end-users with necessary information and instructions to use the product in a safe and effective manner. | PHAC (Public Health Agency of Canada).

Information regarding UKHSA's vaccine strategy in response to the UK mpox outbreak.

Recommendations for the use of pre- and post-exposure vaccination during an mpox incident.

Advice to help lower the chance of passing mpox infection to others during post-exposure vaccination clinics.

Guidance for public health professionals on smallpox and mpox immunisation.

BHIVA's (British HIV Association) rapid guidance on the safety and efficacy of mpox vaccines and therapeutics for people with HIV who have contracted mpox.